Disclosed is an indirect enzyme-linked immunosorbent assay (ELISA) detection kit based on p30 protein and p22 protein of African swine fever (ASF) p30 and p22, belonging to the technical field of animal biological products manufacturing. The indirect ELISA detection kit includes the p30 protein with an amino acid sequence as shown in SEQ ID NO: 2 and the p22 protein with an amino acid sequence as shown in SEQ ID NO: 4.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

An assay system for detecting the presence or absence of at least a first analyte and a second analyte in a sample is disclosed. The assay system comprises an assay device and a separate label solution comprising a detection molecule. The assay device comprises: a first detection region for receiving the sample in a vertical direction perpendicular to a longitudinal axis; a second detection region for receiving the sample from the first detection region in a horizontal direction parallel to the longitudinal axis; a first immobilized molecule in one of the first and second detection regions configured to bind to either the detection molecule or the first analyte; and a second immobilized molecule in the other one of the first and second detection regions and configured to bind to the second analyte to generate a complex, wherein the detection molecule is configured to bind to the complex.

Provided herein are methods of detecting Ebola virus in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) that are conjugated with antibodies, or antigen binding portions thereof, that bind to an epitope of a secreted glycoprotein (sGP) from the Ebola virus under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the epitope of the sGP from the Ebola virus in the sample to produce bound sGP. The methods also include detecting the sGP from the Ebola virus when aggregations of the bound sGP form with one another. Related reaction mixtures, devices, kits, and systems are also provided.

Disclosed is an antigen peptide with an infectious bronchitis virus (IBV)-specific neutralizing epitope, in which the peptide is a cyclic polypeptide, and the amino acid sequence of the peptide is CSCPYVSYGRFCIQPDGSIKQC. Also disclosed are an IBV specific antibody and a preparation method thereof. Further disclosed is an ELISA method as an alternative to the neutralization potency assay. The disclosure also discloses an ELISA detection kit, and using the established pELISA method to detect IBV antibodies, it is found that the method is positively correlated with anti-IBV neutralizing antibodies, which may be used to evaluate the immune effect of IBV vaccines on IBV infected chickens and to determine the antibody level, thereby benefiting the health management of chicken flocks.

The present invention relates to improved single domain antibodies that target SARS-CoV-2, multivalent polypeptides and fusion proteins comprising the single domain antibodies. The present invention also provides coronavirus binding molecules that bind two different epitopes on the receptor binding domain of a spike protein of a coronavirus. The coronavirus binding molecules are based on joining two antigen binding molecules together via a linker. The present invention provides the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in treating and/or preventing coronavirus, as well as the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in the detection and diagnosis of coronavirus using various methods, assays and kits.

The present disclosure provides methods related to determining the level of afucosylated Fc glycans in IgG antibodies in a biological sample from a subject. This level can be used in methods aimed at monitoring and/or treating subject suffering from an acute flavivirus infection and/or who are at risk for progression to clinically significant infection or disease. This level can also be used in a vaccination method to ensure that those who receive a flavivirus vaccine have a reduced risk of reacting to the vaccine be developing clinically significant infection or disease. The disclosure also provides treatment methods based on inhibiting FcγRIIA or FcγRIIIA receptor signaling. Also provided are novel cell lines that are useful in measuring afucosylated Fc glycans.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

A recombinant polypeptide can be used in the diagnosis of the presence of a Zika virus in a patient. The recombinant polypeptide includes SEQ ID NO: 1 or a variant thereof. The recombinant peptide may be a monomer, a dimer, or a hexamer.

A groove-type field effect transistor biosensor based on an atomic layer deposited semiconductor channel is provided. By utilizing the characteristics of excellent step coverage and precise control of an atomic-level film thickness of Atomic Layer Deposition, a high-k dielectric and an indium tin oxide (ITO) semiconductor are sequentially deposited on the three-dimensional groove structure to prepare the biosensor with three-dimensional groove structure field effect transistor. A device with the three-dimensional groove structure can overcome the influence of Debye Screening Effect, achieve a longer Debye length than that with a planar structure, and can detect low-concentration disease markers in high ionic strength solutions, and it has the advantages of high sensitivity and rapid detection, and shows a broad application prospect in the fields of instant detection, invitro diagnosis, biochemical analysis, etc.